Spero Therapeutics
SPRO
59 hedge funds and large institutions have $110M invested in Spero Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 8 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
3% less funds holding
Funds holding: 61 → 59 (-2)
5.14% less ownership
Funds ownership: 60.74% → 55.6% (-5.1%)
10% less capital invested
Capital invested by funds: $122M → $110M (-$12.4M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$627K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$533K |
| 3 |
Renaissance Technologies
New York
|
+$399K |
| 4 |
State Street
Boston,
Massachusetts
|
+$292K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.86M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$962K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$615K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$323K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$204K |
SPRO Hedge Fund Activity: Q3 2019 in Review
59 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2019, worth a combined $110M — down 10% from $122M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SPRO and 6 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 27 added.
The largest buyer was Vanguard Group, adding an estimated $627K. The largest seller was OrbiMed, cutting an estimated $3.86M.
- 59 institutional investors held Spero Therapeutics (SPRO) as of Q3 2019, down from 61 in Q2 2019.
- Funds reported $110M of Spero Therapeutics stock for Q3 2019, down 10% quarter-over-quarter.
- 6 funds opened new Spero Therapeutics positions in Q3 2019 and 8 closed out, a net change of -2 holders.
- The largest Spero Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $627K added.
- The largest Spero Therapeutics seller in Q3 2019 was OrbiMed, an estimated $3.86M sold.
Based on aggregated 13F filings for Q3 2019.